BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006;78:236-44. [PMID: 16545878 DOI: 10.1016/j.radonc.2006.01.009] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Halder A, Biswas R, Ghosh A, Dastidar AG. Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study. J Contemp Brachytherapy 2018;10:225-31. [PMID: 30038642 DOI: 10.5114/jcb.2018.76843] [Reference Citation Analysis]
2 Ishikawa K, Nakamatsu K, Shiraishi O, Yasuda T, Nishimura Y. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. Int J Clin Oncol 2015;20:531-7. [PMID: 25073955 DOI: 10.1007/s10147-014-0736-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Neumann H, Neurath MF, Vieth M, Lever FM, Meijer GJ, Lips IM, Mcmahon BP, Ruurda J, van Hillegersberg R, Siersema P, Levine MS, Scharitzer M, Pokieser P, Zerbib F, Savarino V, Zentilin P, Savarino E, Chan WW. Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease: Innovative techniques in evaluating the esophagus. Ann N Y Acad Sci 2013;1300:11-28. [DOI: 10.1111/nyas.12233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
4 Kelly P, Appleyard V, Murray K, Paulin F, Lamont D, Baker L, Suttie S, Exon D, Thompson A. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010;103:232-238. [PMID: 20551956 DOI: 10.1038/sj.bjc.6605741] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
5 Han C, Schiffner DC, Schultheiss TE, Chen YJ, Liu A, Wong JY. Residual setup errors and dose variations with less-than-daily image guided patient setup in external beam radiotherapy for esophageal cancer. Radiother Oncol 2012;102:309-14. [PMID: 21872956 DOI: 10.1016/j.radonc.2011.07.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
6 Effeney R, Shaw T, Burmeister BH, Burmeister E, Harvey J, Mai GT, Thomas J, Barbour AP, Smithers BM, Pryor DI. Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus. Clin Oncol (R Coll Radiol) 2018;30:642-9. [PMID: 30017206 DOI: 10.1016/j.clon.2018.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Smithers BM, Thomson I. Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer. Thoracic Surgery Clinics 2013;23:509-23. [DOI: 10.1016/j.thorsurg.2013.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
8 Cong E, Oar AJ, Lee MT, Chicco A, Lin M, Yap J, Lin P, Ho Shon I. Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma. J Med Imaging Radiat Oncol 2021;65:23-37. [PMID: 33063470 DOI: 10.1111/1754-9485.13110] [Reference Citation Analysis]
9 Koshy M, Greenwald BD, Hausner P, Krasna MJ, Horiba N, Battafarano RJ, Burrows W, Suntharalingam M. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Am J Clin Oncol 2011;34:259-64. [PMID: 20686405 DOI: 10.1097/COC.0b013e3181e841ce] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
10 Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol). 2011;23:182-188. [PMID: 21232928 DOI: 10.1016/j.clon.2010.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
11 Tergas AI, Neugut AI, Chen L, Burke WM, Hershman DL, Wright JD. Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. Cancer Invest 2016;34:137-47. [PMID: 26986809 DOI: 10.3109/07357907.2015.1131291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
12 Lerut T, Moons J, Coosemans W, Decaluwé H, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Multidisciplinary treatment of advanced cancer of the esophagus and gastroesophageal junction: a European center's approach. Surg Oncol Clin N Am 2008;17:485-502, vii-viii. [PMID: 18486879 DOI: 10.1016/j.soc.2008.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
13 Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Salze P, Noël G. [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study]. Cancer Radiother 2013;17:221-8. [PMID: 23684111 DOI: 10.1016/j.canrad.2013.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kissel M, Chirat E, Annede P, Burtin P, Fumagalli I, Bronsart E, Mignot F, Schernberg A, Dumas I, Haie-Meder C, Chargari C. Esophageal brachytherapy: Institut Gustave Roussy's experience. Brachytherapy 2020;19:499-509. [PMID: 32444283 DOI: 10.1016/j.brachy.2020.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais M, Artru P, Blondin V, Dupuis O, Abdiche MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A. Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX. European Journal of Cancer 2016;56:115-21. [DOI: 10.1016/j.ejca.2015.12.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
16 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
17 Melo AM, O'Brien AM, Phelan JJ, Kennedy SA, Wood NAW, Veerapen N, Besra GS, Clarke NE, Foley EK, Ravi A, MacCarthy F, O'Toole D, Ravi N, Reynolds JV, Conroy MJ, Hogan AE, O'Sullivan J, Dunne MR. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. Front Immunol 2019;10:1580. [PMID: 31354725 DOI: 10.3389/fimmu.2019.01580] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
18 Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2016;95:488-497. [PMID: 27084662 DOI: 10.1016/j.ijrobp.2015.11.043] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
19 Kong C, Guo WJ, Zha WW, Zhu XZ, Huang SF, Zhang YW, Xu JH, He X. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature. Lung Cancer 2014;84:7-12. [PMID: 24548340 DOI: 10.1016/j.lungcan.2014.01.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Meade S, Sanghera P, Glaholm J, Hartley A. Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer. Tumor Biol 2014;35:2017-23. [DOI: 10.1007/s13277-013-1267-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191. [PMID: 25175056 DOI: 10.1186/1748-717X-9-191] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
22 Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:818-823. [PMID: 18718726 DOI: 10.1016/j.ijrobp.2008.04.062] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
23 Willers H, Keane FK, Kamran SC. Toward a New Framework for Clinical Radiation Biology. Hematol Oncol Clin North Am 2019;33:929-45. [PMID: 31668212 DOI: 10.1016/j.hoc.2019.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
24 Nachbar M, Mönnich D, Kalwa P, Zips D, Thorwarth D, Gani C. Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer. Strahlenther Onkol 2019;195:327-34. [PMID: 30361744 DOI: 10.1007/s00066-018-1386-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
25 Srinivas C, Laskar SG, Mistry RC, Pramesh CS, Dinshaw KA. Systematic overview of preoperative chemoradiation trials in esophageal cancer: in response to article by Ian Geh et al. Radiother Oncol 2007;82:106-7; author reply 107-8. [PMID: 17156874 DOI: 10.1016/j.radonc.2006.11.003] [Reference Citation Analysis]
26 Park J, Yea JW, Oh SA, Park JW. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Radiat Oncol 2021;16:219. [PMID: 34775988 DOI: 10.1186/s13014-021-01947-7] [Reference Citation Analysis]
27 Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci 2010;55:3304-14. [PMID: 20300841 DOI: 10.1007/s10620-010-1187-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
28 Lever FM, Lips IM, Crijns SP, Reerink O, van Lier AL, Moerland MA, van Vulpen M, Meijer GJ. Quantification of esophageal tumor motion on cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2014;88:419-424. [PMID: 24321785 DOI: 10.1016/j.ijrobp.2013.10.036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
29 Gao HM, Shen WB, Xu JR, Li YM, Li SG, Zhu SC. Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer. Int J Clin Oncol 2021;26:1640-9. [PMID: 34043101 DOI: 10.1007/s10147-021-01943-7] [Reference Citation Analysis]
30 Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G, Barni S. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. European Journal of Surgical Oncology 2017;43:1607-16. [DOI: 10.1016/j.ejso.2017.03.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
31 Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53. [PMID: 26989391 DOI: 10.1159/000440638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
32 Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy: Treatment Time in the Era of CCRT. Cancer 2013;119:325-31. [DOI: 10.1002/cncr.27652] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 7.8] [Reference Citation Analysis]
33 Hong JC, Foote J, Broadwater G, Sosa JA, Gaillard S, Havrilesky LJ, Chino JP. Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation? JCO Clin Cancer Inform 2017;1:1-15. [PMID: 30657372 DOI: 10.1200/CCI.16.00072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
34 Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231-238. [PMID: 18836090 DOI: 10.1093/annonc/mdn622] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 5.6] [Reference Citation Analysis]
35 Krause M, Zips D, Thames HD, Kummermehr J, Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiotherapy and Oncology 2006;80:112-22. [DOI: 10.1016/j.radonc.2006.07.017] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
36 Liu M, Chen Y, Fu X, Zhao K, Jiang G. Proposed revision of CT-based cervical and thoracic lymph node levels for esophageal cancer in UICC 7th version. Radiotherapy and Oncology 2014;113:175-81. [DOI: 10.1016/j.radonc.2014.11.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
37 Barney CL, Zamora P, Ewing A, Old M, Chakravarti A, Bhatt A. Synchronous Supraglottic and Esophageal Squamous Cell Carcinomas Treated with a Monoisocentric Hybrid Intensity-Modulated Radiation Technique. Front Oncol 2017;7:307. [PMID: 29359120 DOI: 10.3389/fonc.2017.00307] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Chen J, Guo H, Zhai T, Chang D, Chen Z, Huang R, Zhang W, Lin K, Guo L, Zhou M, Li D, Li D, Chen C. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget 2016;7:22711-9. [PMID: 26992206 DOI: 10.18632/oncotarget.8050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
39 Bridges S, Thomas B, Radhakrishna G, Hawkins M, Holborow A, Hurt C, Mukherjee S, Nixon L, Crosby T, Gwynne S. SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.03.019] [Reference Citation Analysis]
40 Bittner N, Wallner K, Merrick G, Orio P, Nurani R, True L. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure. Am J Clin Oncol 2008;31:231-6. [PMID: 18525300 DOI: 10.1097/COC.0b013e31815a43ab] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. Journal of Thoracic Oncology 2009;4:880-8. [DOI: 10.1097/jto.0b013e3181a6f204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 López Carrizosa MC, Samper Ots PM, Rodríguez Pérez A, Sotoca A, Sáez Garrido J, de Miguel MM. High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED). Clin Transl Oncol 2007;9:385-91. [DOI: 10.1007/s12094-007-0071-y] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Power R, Lowery MA, Reynolds JV, Dunne MR. The Cancer-Immune Set Point in Oesophageal Cancer. Front Oncol. 2020;10:891. [PMID: 32582553 DOI: 10.3389/fonc.2020.00891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, Kok HP. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13:96. [PMID: 29769103 DOI: 10.1186/s13014-018-1040-z] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 29.3] [Reference Citation Analysis]
45 Bouchard M, McAleer MF, Starkschall G. Impact of gastric filling on radiation dose delivered to gastroesophageal junction tumors. Int J Radiat Oncol Biol Phys 2010;77:292-300. [PMID: 20092963 DOI: 10.1016/j.ijrobp.2009.08.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
46 Takeda K, Matsushita H, Umezawa R, Yamamoto T, Ishikawa Y, Takahashi N, Suzuki Y, Jingu K. Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer. Radiat Oncol J 2021;39:265-9. [PMID: 34986547 DOI: 10.3857/roj.2021.00325] [Reference Citation Analysis]
47 Jiang N, Ge XL, Zhang ZY, Liu J, Wang PP, Sun XC, Yang M. Prognostic Factors for Patients with Esophageal Cancer Receiving Definitive Radiotherapy Alone: A Retrospective Analysis. Cancer Manag Res 2021;13:3229-34. [PMID: 33880065 DOI: 10.2147/CMAR.S300672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hsieh CH, Hsieh YJ, Liu CY, Tai HC, Huang YC, Shueng PW, Wu LJ, Wang LY, Tsai TH, Chen YJ. Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. J Transl Med 2010;8:29. [PMID: 20338060 DOI: 10.1186/1479-5876-8-29] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
49 Muijs CT, Pruim J, Beukema JC, Berveling MJ, Plukker JT, Langendijk JA. Oesophageal tumour progression between the diagnostic 18F-FDG-PET and the 18F-FDG-PET for radiotherapy treatment planning. Radiother Oncol. 2013;106:283-287. [PMID: 23199654 DOI: 10.1016/j.radonc.2012.10.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
50 Yang Y, Xu X, Zhou X, Bao W, Zhang D, Gu F, Du X, Chen Q, Qiu G. Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy. Front Oncol 2020;10:1431. [PMID: 32974158 DOI: 10.3389/fonc.2020.01431] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, Abu Jawad J, Wohlschlaeger J, Welter S, Stamatis G. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation. Eur J Cancer. 2013;49:2107-2115. [PMID: 23510803 DOI: 10.1016/j.ejca.2013.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
52 Furlong H, Bass G, Breathnach O, O'Neill B, Leen E, Walsh TN. Targeting therapy for esophageal cancer in patients aged 70 and over. J Geriatr Oncol 2013;4:107-13. [PMID: 24071535 DOI: 10.1016/j.jgo.2012.12.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
53 Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927-34. [PMID: 19934911 DOI: 10.1007/DCR.0b013e3181ba14ed] [Cited by in Crossref: 146] [Cited by in F6Publishing: 38] [Article Influence: 12.2] [Reference Citation Analysis]
54 Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009;92:276-90. [PMID: 19375187 DOI: 10.1016/j.radonc.2009.02.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
55 Sanghera P, Wong DW, McConkey CC, Geh JI, Hartley A. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) 2008;20:176-83. [PMID: 18248971 DOI: 10.1016/j.clon.2007.11.013] [Cited by in Crossref: 134] [Cited by in F6Publishing: 121] [Article Influence: 9.6] [Reference Citation Analysis]
56 Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D. Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res. 2010;182:127-142. [PMID: 20676877 DOI: 10.1007/978-3-540-70579-6_11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
57 Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, Debus J, Sterzing F. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res 2015;56:742-9. [PMID: 25907360 DOI: 10.1093/jrr/rrv022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
58 Reid P, Staudacher AH, Marcu LG, Olver I, Moghaddasi L, Brown MP, Bezak E. Characteristic differences in radiation-induced DNA damage response in human papillomavirus-negative and human papillomavirus-positive head and neck cancers with accumulation of fractional radiation dose. Head Neck 2021;43:3086-96. [PMID: 34235809 DOI: 10.1002/hed.26802] [Reference Citation Analysis]
59 Warren S, Hurt CN, Crosby T, Partridge M, Hawkins MA. Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2017;99:729-37. [PMID: 29280467 DOI: 10.1016/j.ijrobp.2017.07.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
60 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
61 Mukherjee S, Hurt CN, Gwynne S, Sebag-Montefiore D, Radhakrishna G, Gollins S, Hawkins M, Grabsch HI, Jones G, Falk S, Sharma R, Bateman A, Roy R, Ray R, Canham J, Griffiths G, Maughan T, Crosby T. NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. Eur J Cancer 2017;74:38-46. [PMID: 28335886 DOI: 10.1016/j.ejca.2016.11.031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
62 Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38:599-604. [PMID: 22116018 DOI: 10.1016/j.ctrv.2011.10.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
63 Borg D, Sundberg J, Brun E, Kjellén E, Petersson K, Hermansson M, Johansson J, Eberhard J, Johnsson A. Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial. Acta Oncol 2020;59:212-8. [PMID: 31564184 DOI: 10.1080/0284186X.2019.1670861] [Reference Citation Analysis]
64 Caro M, Font A, Comas S, Viciano M, Remon J, Céliz P, Robles J, Musulén E, Sendrós MJ, Mesalles E, Jiménez JA, Boix J, Arellano A, Fernández-llamazares J. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II–III esophageal carcinoma. Clin Transl Oncol 2016;18:1106-13. [DOI: 10.1007/s12094-016-1488-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU, Bruewer M. Impact of PET-CT on Primary Staging and Response Control on Multimodal Treatment of Esophageal Cancer. World J Surg 2011;35:608-16. [DOI: 10.1007/s00268-010-0946-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
66 Meade S, Sanghera P, Mcconkey C, Fowler J, Fountzilas G, Glaholm J, Hartley A. Revising the Radiobiological Model of Synchronous Chemotherapy in Head-and-Neck Cancer: A New Analysis Examining Reduced Weighting of Accelerated Repopulation. International Journal of Radiation Oncology*Biology*Physics 2013;86:157-63. [DOI: 10.1016/j.ijrobp.2012.11.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
67 Jones B, Sanghera P. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 2007;68:441-8. [PMID: 17324531 DOI: 10.1016/j.ijrobp.2006.12.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
68 Molls M, Nieder C, Belka C, Norum J. Quantitative Cell Kill of Radio- and Chemotherapy. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. Berlin: Springer Berlin Heidelberg; 2009. pp. 169-90. [DOI: 10.1007/978-3-540-74386-6_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Hawkins MA, Bedford JL, Warrington AP, Tait DM. Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br J Radiol. 2012;85:44-52. [PMID: 21427179 DOI: 10.1259/bjr/25428720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
70 Knauer M, Haid A, Ammann K, Lang A, Offner F, Türtscher M, Cerkl P, Wenzl E. Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. World J Surg Oncol 2007;5:114. [PMID: 17927839 DOI: 10.1186/1477-7819-5-114] [Reference Citation Analysis]
71 Hafeez S, Bedford JL, Tait DM, Hawkins MA. Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. Acta Oncologica 2013;53:149-54. [DOI: 10.3109/0284186x.2013.776174] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials: Pooled analysis phase II trials. Diseases of the Esophagus 2012;25:130-6. [DOI: 10.1111/j.1442-2050.2011.01220.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
73 Tepper JE, O'neil B. Transition in Biology and Philosophy in the Treatment of Gastroesophageal Junction Adenocarcinoma. JCO 2009;27:836-7. [DOI: 10.1200/jco.2008.19.5982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
74 Créhange G, Maingon P, Bosset JF. [Radiochemotherapy for oesophageal cancer: a locoregional failure history]. Cancer Radiother 2008;12:640-8. [PMID: 18845466 DOI: 10.1016/j.canrad.2008.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
75 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
76 Padmanaban S, Warren S, Walsh A, Partridge M, Hawkins MA. Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. Radiat Oncol 2014;9:286. [PMID: 25533761 DOI: 10.1186/s13014-014-0286-3] [Cited by in Crossref: 9] [Article Influence: 1.1] [Reference Citation Analysis]
77 Ruffier-Loubière A, Janoray G, Chapet S, de Calan L, Dumont P, Dorval É, Orain I, Calais G. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients]. Cancer Radiother 2015;19:322-30. [PMID: 26215366 DOI: 10.1016/j.canrad.2015.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Parzen JS, Chuong MD, Chang J, Rosen L, Urbanic J, Hartsell W, Tsai H, Sinesi C, Zeng J, Mishra M, Vargas C, Stevens C, Kabolizadeh P. Dosimetry and Acute Toxicity Profile of Patients With Esophageal Cancer Treated With Proton Beam Radiation Therapy: Outcomes From the Proton Collaborative Group REG001-09 Trial. Adv Radiat Oncol 2021;6:100751. [PMID: 34646969 DOI: 10.1016/j.adro.2021.100751] [Reference Citation Analysis]
79 Reid P, Staudacher AH, Marcu LG, Olver I, Moghaddasi L, Brown MP, Li Y, Bezak E. Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers. Cells 2020;9:E1788. [PMID: 32727072 DOI: 10.3390/cells9081788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins MA. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423-429. [PMID: 25304796 DOI: 10.1016/j.ijrobp.2014.06.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
81 Zoltan L, Farkas R, Schally AV, Pozsgai E, Papp A, Bognár L, Tornoczki T, Mangel L, Bellyei S. Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer. Pathol Oncol Res 2019;25:279-88. [PMID: 29103201 DOI: 10.1007/s12253-017-0342-z] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
82 Carrington R, Staffurth J, Warren S, Partridge M, Hurt C, Spezi E, Gwynne S, Hawkins MA, Crosby T. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiat Oncol 2015;10:236. [PMID: 26586375 DOI: 10.1186/s13014-015-0537-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
83 Nicolay NH, Rademacher J, Oelmann-avendano J, Debus J, Huber PE, Lindel K. High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer: Experience from a large single-center cohort. Strahlenther Onkol 2016;192:458-66. [DOI: 10.1007/s00066-016-0979-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
84 Hartley A, Sanghera P, Glaholm J, Mehanna H, Mcconkey C, Fowler J. Radiobiological Modelling of the Therapeutic Ratio for the Addition of Synchronous Chemotherapy to Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Oncology 2010;22:125-30. [DOI: 10.1016/j.clon.2009.10.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
85 Bates T, Williams NJ, Bendall S, Bassett EE, Coltart RS. Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer. Breast 2012;21:330-5. [PMID: 22410111 DOI: 10.1016/j.breast.2012.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
86 Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627-637. [PMID: 23623280 DOI: 10.1016/s1470-2045(13)70136-0] [Cited by in Crossref: 235] [Cited by in F6Publishing: 129] [Article Influence: 26.1] [Reference Citation Analysis]
87 Gwynne S, Falk S, Gollins S, Wills L, Bateman A, Cummins S, Grabsch H, Hawkins MA, Maggs R, Mukherjee S, Radhakrishna G, Roy R, Sharma RA, Spezi E, Crosby T. Oesophageal Chemoradiotherapy in the UK--current practice and future directions. Clin Oncol (R Coll Radiol) 2013;25:368-77. [PMID: 23489868 DOI: 10.1016/j.clon.2013.01.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
88 Courrech Staal EFW, Aleman BMP, Boot H, van Velthuysen MF, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. British Journal of Surgery 2010;97:1482-96. [DOI: 10.1002/bjs.7175] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 8.1] [Reference Citation Analysis]
89 Hennequin C, Quero L, Baruch-Hennequin V, Maylin C. [Do locally advanced esophageal cancer still need surgery?]. Cancer Radiother 2008;12:831-6. [PMID: 19046920 DOI: 10.1016/j.canrad.2008.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
90 Mishra S, Ahmad F, Singh S, Singh RK, Das KJM, Kumar S. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. Cancer Rep (Hoboken) 2021;4:e1332. [PMID: 33369258 DOI: 10.1002/cnr2.1332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D, Thompson A. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012;106:955-961. [PMID: 22294182 DOI: 10.1038/bjc.2012.15] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
92 Mongan AM, Lynam-Lennon N, Doyle SL, Casey R, Carr E, Cannon A, Conroy MJ, Pidgeon GP, Brennan L, Lysaght J, Reynolds JV, O'Sullivan J. Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma. Int J Med Sci 2019;16:519-28. [PMID: 31171903 DOI: 10.7150/ijms.29296] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
93 Metzger R, Warnecke-Eberz U, Alakus H, Kütting F, Brabender J, Vallböhmer D, Grimminger PP, Mönig SP, Drebber U, Hölscher AH. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16:26-34; discussion 34. [PMID: 21956434 DOI: 10.1007/s11605-011-1700-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
94 Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiotherapy and Oncology 2010;96:6-12. [DOI: 10.1016/j.radonc.2010.03.020] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
95 Smit JK, Muijs CT, Burgerhof JGM, Paardekooper G, Timmer PR, Muller K, Woutersen D, Mul VE, Beukema JC, Hospers GAP, van Dijk BAC, Langendijk JA, Plukker JTM. Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Ann Surg Oncol 2013;20:1985-92. [DOI: 10.1245/s10434-012-2824-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
96 Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009;99:302-306. [PMID: 19170110 DOI: 10.1002/jso.21235] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
97 Pettit L, Meade S, Sanghera P, Glaholm J, Geh JI, Hartley A. Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation? Br J Radiol 2013;86:20120372. [PMID: 23239699 DOI: 10.1259/bjr.20120372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
98 Dunne MR, Michielsen AJ, O'Sullivan KE, Cathcart MC, Feighery R, Doyle B, Watson JA, O'Farrell NJ, Ravi N, Kay E, Reynolds JV, Ryan EJ, O'Sullivan J. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients. Cancer Immunol Immunother 2017;66:841-50. [PMID: 28315927 DOI: 10.1007/s00262-017-1983-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
99 Zhang R, Jia M, Li P, Han J, Huang K, Li Q, Qiao Y, Xu T, Ruan P, Hu Q, Fan G, Song Q, Fu Z. Radiotherapy improves the survival of patients with metastatic esophageal squamous cell carcinoma: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
100 Thomas M, Borggreve AS, van Rossum PSN, Perneel C, Moons J, Van Daele E, van Hillegersberg R, Deng W, Pattyn P, Mook S, Boterberg T, Ruurda JP, Nafteux P, Lin SH, Haustermans K. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. Acta Oncol 2019;58:1358-65. [PMID: 31432736 DOI: 10.1080/0284186X.2019.1646432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Warren S, Partridge M, Bolsi A, Lomax AJ, Hurt C, Crosby T, Hawkins MA. An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning. Int J Radiat Oncol Biol Phys 2016;95:199-207. [PMID: 27084641 DOI: 10.1016/j.ijrobp.2016.01.044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
102 Mansour JC, Schwarz RE. Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means? Ann Surg Oncol 2009;16:1465-79. [DOI: 10.1245/s10434-009-0374-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
103 Chun SG, Skinner HD, Minsky BD. Radiation Therapy for Locally Advanced Esophageal Cancer. Surg Oncol Clin N Am 2017;26:257-76. [PMID: 28279468 DOI: 10.1016/j.soc.2016.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
104 Maher SG, McDowell DT, Collins BC, Muldoon C, Gallagher WM, Reynolds JV. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg. 2011;254:809-816; discussion 816-817. [PMID: 22005152 DOI: 10.1097/sla.0b013e31823699f2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
105 He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 2014;9:1398-405. [PMID: 25122435 DOI: 10.1097/JTO.0000000000000267] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
106 Cremonesi M, Garibaldi C, Timmerman R, Ferrari M, Ronchi S, Grana CM, Travaini L, Gilardi L, Starzyńska A, Ciardo D, Orecchia R, Jereczek-Fossa BA, Leonardi MC. Interim 18F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. Radiother Oncol 2017;125:200-12. [PMID: 29029833 DOI: 10.1016/j.radonc.2017.09.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
107 Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894. [PMID: 19953708 DOI: 10.1097/sla.0b013e3181bc9c0d] [Cited by in Crossref: 87] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
108 Rackley T, Leong T, Foo M, Crosby T. Definitive Chemoradiotherapy for Oesophageal Cancer — A Promising Start on an Exciting Journey. Clinical Oncology 2014;26:533-40. [DOI: 10.1016/j.clon.2014.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
109 Epari K, Cade R. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction. ANZ Journal of Surgery 2009;79:251-7. [DOI: 10.1111/j.1445-2197.2009.04855.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
110 Torrente S, Turri L, Deantonio L, Cena T, Gambaro G, Magnani C, Krengli M. Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients. Rep Pract Oncol Radiother 2012;17:226-32. [PMID: 24377028 DOI: 10.1016/j.rpor.2012.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
111 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
112 Adebahr S, Schimek-jasch T, Nestle U, Brunner TB. Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Practice & Research Clinical Gastroenterology 2016;30:565-80. [DOI: 10.1016/j.bpg.2016.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
113 Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncology 2010;6:25-35. [DOI: 10.2217/fon.09.133] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
114 Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol. 2010;186:374-381. [PMID: 20582393 DOI: 10.1007/s00066-010-2137-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
115 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
116 Meade S, Mcconkey C, Sanghera P, Mehanna H, Hartley A. Revised radiobiological modelling of the contribution of synchronous chemotherapy to the rate of grades 3-4 mucositis in head and neck cancer: Radiobiological modelling of mucositis. Journal of Medical Imaging and Radiation Oncology 2013;57:733-8. [DOI: 10.1111/1754-9485.12096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
117 Metzger R, Bollschweiler E, Drebber U, Mönig SP, Schröder W, Alakus H, Kocher M, Baldus SE, Hölscher AH. Neoadjuvant chemoradiotherapy for esophageal cancer: Impact on extracapsular lymph node involvement. World J Gastroenterol 2010; 16(16): 1986-1992 [PMID: 20419835 DOI: 10.3748/wjg.v16.i16.1986] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
118 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel) 2019;11:E993. [PMID: 31315281 DOI: 10.3390/cancers11070993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
119 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
120 Reis I, Pereira H, Azevedo I, Conde J, Bravo I, Craveiro R, Pereira D. Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case report. Rep Pract Oncol Radiother 2014;19:65-8. [PMID: 24936322 DOI: 10.1016/j.rpor.2013.09.004] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
121 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
122 Wolf MC, Zehentmayr F, Schmidt M, Hölzel D, Belka C. Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol 2012;7:60. [PMID: 22501022 DOI: 10.1186/1748-717X-7-60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
123 Cellini F, Manfrida S, Casà C, Romano A, Arcelli A, Zamagni A, De Luca V, Colloca GF, D'Aviero A, Fuccio L, Lancellotta V, Tagliaferri L, Boldrini L, Mattiucci GC, Gambacorta MA, Morganti AG, Valentini V. Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers (Basel) 2022;14:431. [PMID: 35053594 DOI: 10.3390/cancers14020431] [Reference Citation Analysis]